LEXX Overview

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.

Wall Street analysts forecast LEXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LEXX is1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Lexaria Bioscience Corp revenue for the last quarter amounts to 0.00 USD, decreased -100.00

Lexaria Bioscience Corp. EPS for the last quarter amounts to -0.07 USD, decreased -56.25

Lexaria Bioscience Corp (LEXX) has 7 emplpoyees as of March 21 2026.

Today LEXX has the market capitalization of 17.75M USD.